敗血症治療薬の世界市場レポート 2025年

敗血症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.7％で64億1,000万米ドルに成長します。予測期間における成長の原動力は、抗菌薬耐性の蔓延、バイオマーカーに基づく診断の採用拡大、敗血症治療における免疫療法の重視の高まり、新興国市場における病院インフラの拡大、敗血症管理の強化に向けた政府の取り組みなどの要因です。この期間の主な動向には、精密医療の発展、敗血症早期発見のためのAIの統合、併用療法の増加、新しい敗血症治療薬の臨床試験の増加、迅速分子診断の利用拡大などがあります。

感染症の蔓延は、敗血症治療薬市場を前進させると予想されます。細菌、ウイルス、真菌、寄生虫などの有害な微生物によって引き起こされる感染症は、主に気候変動によって増加傾向にあります。気温や生態系の変化によって、蚊のような病気を媒介する媒介生物の生息域が拡大し、マラリアやデング熱のような病気の蔓延につながっています。敗血症治療薬は、これらの感染症に対処するために、感染そのものを標的とし、炎症を抑え、生命を脅かす合併症を防ぐために臓器機能をサポートします。米国国立医学図書館によると、2023年1月現在、感染症による死亡者数は年間5,200万人を超え、世界人口の半数近くが危険にさらされています。毎年、約1,400万人の5歳未満児が死亡しており、その70％はワクチン接種によって回避可能な予防可能な病気に関連しています。このように、感染症の流行増加は敗血症治療薬市場の成長を促進する重要な要因です。

敗血症診断市場の企業は、敗血症の検出と管理を改善するための革新的な診断技術の開発に注力しています。病原体を迅速かつ正確に検出できる迅速分子検査の進歩は、早期診断、患者の転帰改善、発見の遅れによる死亡率の減少に不可欠です。これらの迅速分子検査は、PCRや等温増幅などの高度な技術を用いて、病原体の遺伝物質を検出することにより病原体を同定します。例えば、2023年11月、米国のバイオテクノロジー企業であるInflammatix Inc.は、TriVerity急性感染症・敗血症検査システムの完成を発表しました。このシステムにはMyrna InstrumentとTriVerity Cartridgeが含まれ、感染症や敗血症が疑われる患者の細菌感染やウイルス感染の可能性や急性増悪のリスクを評価するために救急部門用に設計されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界敗血症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の敗血症治療薬市場：成長率分析
• 世界の敗血症治療薬市場の実績：規模と成長, 2019-2024
• 世界の敗血症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界敗血症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の敗血症治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• セファロスポリン
• アミノグリコシド
• 糖ペプチド
• その他の薬物クラス
• 世界の敗血症治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• トピック
• 世界の敗血症治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の敗血症治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他の用途
• 世界の敗血症治療薬市場セファロスポリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一世代セファロスポリン
• 第二世代セファロスポリン
• 第三世代セファロスポリン
• 第4世代セファロスポリン
• 第5世代セファロスポリン
• 世界の敗血症治療薬市場アミノグリコシドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゲンタマイシン
• アミカシン
• トブラマイシン
• ストレプトマイシン
• その他のアミノグリコシド
• 世界の敗血症治療薬市場糖ペプチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• バンコマイシン
• テイコプラニン
• ダルババンシン
• オリタヴァンシン
• その他の糖ペプチド
• 世界の敗血症治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルバペネム
• β-ラクタマーゼ阻害剤
• フルオロキノロン
• マクロライド
• ポリミキシン

第7章 地域別・国別分析

• 世界の敗血症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の敗血症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 敗血症治療薬市場：競合情勢
• 敗血症治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Astellas Pharma Inc.
• inthelia
• La Jolla Pharmaceutical Co.
• Cytovale Inc.
• Aridis Pharmaceuticals Inc.
• Partner Therapeutics Inc.
• T2 Biosystems Inc.
• Modus Therapeutics
• InflaRx GmbH
• Adrenomed AG
• Sepsia Therapeutics
• Endpoint Health
• Prenosis Inc.
• Spectral Medical Inc
• Matisse Pharmaceuticals B.V.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 敗血症治療薬市場2029：新たな機会を提供する国
• 敗血症治療薬市場2029：新たな機会を提供するセグメント
• 敗血症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Sepsis therapeutics refer to the medical treatments and medications specifically aimed at managing sepsis, a life-threatening condition triggered by the body's extreme response to infection. The primary objective of these treatments is to control the infection, sustain vital functions, manage inflammation, and avert organ failure, thereby enhancing survival rates and aiding in patient recovery.

The key drug categories used in sepsis treatment include cephalosporins, aminoglycosides, glycopeptides, among others. Cephalosporins, a class of broad-spectrum antibiotics, are frequently prescribed for sepsis and other serious bacterial infections. These drugs can be administered through various methods, such as orally, via injection, or topically. They are distributed through different channels, including hospital pharmacies, retail pharmacies, and online platforms. These medications are primarily used in settings such as hospitals, clinics, and other healthcare environments.

The sepsis therapeutics market research report is one of a series of new reports from The Business Research Company that provides sepsis therapeutics market statistics, including the sepsis therapeutics industry global market size, regional shares, competitors with the sepsis therapeutics market share, detailed sepsis therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the sepsis therapeutics industry. This sepsis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sepsis therapeutics market size has grown rapidly in recent years. It will grow from $4.03 billion in 2024 to $4.43 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth observed in the historical period can be credited to factors such as the rising number of sepsis cases, heightened awareness surrounding early diagnosis and treatment, progress in antibiotic and antifungal therapies, increased healthcare spending, and regulatory backing for the advancement of sepsis treatments.

The sepsis therapeutics market size is expected to see strong growth in the next few years. It will grow to $6.41 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The projected growth in the forecast period is driven by factors such as the increasing prevalence of antimicrobial resistance, greater adoption of biomarker-based diagnostics, a growing emphasis on immunotherapy for sepsis treatment, expansion of hospital infrastructure in developing markets, and government efforts to enhance sepsis management. Key trends during this period include the development of precision medicine, integration of AI for early sepsis detection, a rise in combination therapies, an increase in clinical trials for new sepsis drugs, and an expanded use of rapid molecular diagnostics.

The growing prevalence of infectious diseases is expected to drive the sepsis therapeutics market forward. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, are on the rise, primarily due to climate change. Changing temperatures and ecosystems are expanding the habitats of disease-carrying vectors such as mosquitoes, leading to the spread of illnesses such as malaria and dengue fever. Sepsis therapeutics address these infectious diseases by targeting the infection itself, reducing inflammation, and supporting organ function to prevent life-threatening complications. According to the National Library of Medicine, in January 2023, infectious diseases are responsible for over 52 million deaths annually, with nearly half of the global population at risk. Each year, approximately 14 million children under five die, and 70% of these deaths are linked to preventable diseases that could be avoided through vaccination. Thus, the increasing prevalence of infectious diseases is a key factor driving the growth of the sepsis therapeutics market.

Companies in the sepsis diagnostics market are focused on developing innovative diagnostic technologies to improve sepsis detection and management. Advances in rapid molecular tests, which can detect pathogens quickly and accurately, are crucial for early diagnosis, better patient outcomes, and reduced mortality rates caused by delayed detection. These rapid molecular tests use advanced techniques such as PCR or isothermal amplification to identify pathogens by detecting their genetic material. For example, in November 2023, Inflammatix Inc., a US-based biotechnology company, announced the completion of its TriVerity Acute Infection and Sepsis Test System. This system includes the Myrna Instrument and the TriVerity Cartridge, designed for emergency department use to assess the likelihood of bacterial or viral infections and the risk of acute decompensation in patients with suspected infections and sepsis.

In January 2025, Partner Therapeutics, Inc. (PTx), a US-based biotechnology company specializing in sepsis therapeutics, partnered with the Biomedical Advanced Research and Development Authority (BARDA) to fund a Phase 2 study on the safety and optimal dosing of LEUKINE (sargramostim, rhu GM-CSF) in sepsis patients. This collaboration aims to enhance sepsis treatment by developing tools to measure immune status, enabling more targeted immunomodulatory therapies. BARDA, a US government department dedicated to biomedical advanced research, is supporting this initiative.

Major players in the sepsis therapeutics market are Pfizer Inc., AstraZeneca plc, GSK plc, Eli Lilly and Company, Viatris Inc., Astellas Pharma Inc., inthelia, La Jolla Pharmaceutical Co., Cytovale Inc., Aridis Pharmaceuticals Inc., Partner Therapeutics Inc., T2 Biosystems Inc., Modus Therapeutics, InflaRx GmbH, Adrenomed AG, Sepsia Therapeutics, Endpoint Health, Prenosis Inc., Spectral Medical Inc, Matisse Pharmaceuticals B.V.

North America was the largest region in the sepsis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sepsis therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sepsis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sepsis therapeutics market consists of revenues earned by entities providing services such as pharmaceutical interventions, supportive therapies, and diagnostic solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The sepsis therapeutics market also includes sales of antibiotics, intravenous fluids, vasopressors, and advanced therapies aimed at controlling infection, stabilizing patients, and preventing organ failure. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sepsis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sepsis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sepsis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sepsis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Cephalosporin; Aminoglycosides; Glycopeptide; Other Drug Classes
• 2) By Route Of Administration: Oral; Injectable; Topical
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Hospitals; Clinics; Other Applications
• Subsegments:
• 1) By Cephalosporin: First-Generation Cephalosporins; Second-Generation Cephalosporins; Third-Generation Cephalosporins; Fourth-Generation Cephalosporins; Fifth-Generation Cephalosporins
• 2) By Aminoglycosides: Gentamicin; Amikacin; Tobramycin; Streptomycin; Other Aminoglycosides
• 3) By Glycopeptide: Vancomycin; Teicoplanin; Dalbavancin; Oritavancin; Other Glycopeptides
• 4) By Other Drug Classes: Carbapenems; Beta-Lactamase Inhibitors; Fluoroquinolones; Macrolides; Polymyxins
• Companies Mentioned: Pfizer Inc.; AstraZeneca plc; GSK plc; Eli Lilly and Company; Viatris Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sepsis Therapeutics Market Characteristics

3. Sepsis Therapeutics Market Trends And Strategies

4. Sepsis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Sepsis Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Sepsis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Sepsis Therapeutics Market Growth Rate Analysis
• 5.4. Global Sepsis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Sepsis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Sepsis Therapeutics Total Addressable Market (TAM)

6. Sepsis Therapeutics Market Segmentation

• 6.1. Global Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cephalosporin
• Aminoglycosides
• Glycopeptide
• Other Drug Classes
• 6.2. Global Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• 6.3. Global Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Sepsis Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other Applications
• 6.5. Global Sepsis Therapeutics Market, Sub-Segmentation Of Cephalosporin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Generation Cephalosporins
• Second-Generation Cephalosporins
• Third-Generation Cephalosporins
• Fourth-Generation Cephalosporins
• Fifth-Generation Cephalosporins
• 6.6. Global Sepsis Therapeutics Market, Sub-Segmentation Of Aminoglycosides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gentamicin
• Amikacin
• Tobramycin
• Streptomycin
• Other Aminoglycosides
• 6.7. Global Sepsis Therapeutics Market, Sub-Segmentation Of Glycopeptide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vancomycin
• Teicoplanin
• Dalbavancin
• Oritavancin
• Other Glycopeptides
• 6.8. Global Sepsis Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Carbapenems
• Beta-Lactamase Inhibitors
• Fluoroquinolones
• Macrolides
• Polymyxins

7. Sepsis Therapeutics Market Regional And Country Analysis

• 7.1. Global Sepsis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Sepsis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sepsis Therapeutics Market

• 8.1. Asia-Pacific Sepsis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sepsis Therapeutics Market

• 9.1. China Sepsis Therapeutics Market Overview
• 9.2. China Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sepsis Therapeutics Market

• 10.1. India Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sepsis Therapeutics Market

• 11.1. Japan Sepsis Therapeutics Market Overview
• 11.2. Japan Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sepsis Therapeutics Market

• 12.1. Australia Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sepsis Therapeutics Market

• 13.1. Indonesia Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sepsis Therapeutics Market

• 14.1. South Korea Sepsis Therapeutics Market Overview
• 14.2. South Korea Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sepsis Therapeutics Market

• 15.1. Western Europe Sepsis Therapeutics Market Overview
• 15.2. Western Europe Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sepsis Therapeutics Market

• 16.1. UK Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sepsis Therapeutics Market

• 17.1. Germany Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sepsis Therapeutics Market

• 18.1. France Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sepsis Therapeutics Market

• 19.1. Italy Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sepsis Therapeutics Market

• 20.1. Spain Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sepsis Therapeutics Market

• 21.1. Eastern Europe Sepsis Therapeutics Market Overview
• 21.2. Eastern Europe Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sepsis Therapeutics Market

• 22.1. Russia Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sepsis Therapeutics Market

• 23.1. North America Sepsis Therapeutics Market Overview
• 23.2. North America Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sepsis Therapeutics Market

• 24.1. USA Sepsis Therapeutics Market Overview
• 24.2. USA Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sepsis Therapeutics Market

• 25.1. Canada Sepsis Therapeutics Market Overview
• 25.2. Canada Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sepsis Therapeutics Market

• 26.1. South America Sepsis Therapeutics Market Overview
• 26.2. South America Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sepsis Therapeutics Market

• 27.1. Brazil Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sepsis Therapeutics Market

• 28.1. Middle East Sepsis Therapeutics Market Overview
• 28.2. Middle East Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sepsis Therapeutics Market

• 29.1. Africa Sepsis Therapeutics Market Overview
• 29.2. Africa Sepsis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Sepsis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Sepsis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sepsis Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Sepsis Therapeutics Market Competitive Landscape
• 30.2. Sepsis Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Sepsis Therapeutics Market Other Major And Innovative Companies

• 31.1. Astellas Pharma Inc.
• 31.2. inthelia
• 31.3. La Jolla Pharmaceutical Co.
• 31.4. Cytovale Inc.
• 31.5. Aridis Pharmaceuticals Inc.
• 31.6. Partner Therapeutics Inc.
• 31.7. T2 Biosystems Inc.
• 31.8. Modus Therapeutics
• 31.9. InflaRx GmbH
• 31.10. Adrenomed AG
• 31.11. Sepsia Therapeutics
• 31.12. Endpoint Health
• 31.13. Prenosis Inc.
• 31.14. Spectral Medical Inc
• 31.15. Matisse Pharmaceuticals B.V.

32. Global Sepsis Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sepsis Therapeutics Market

34. Recent Developments In The Sepsis Therapeutics Market

35. Sepsis Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Sepsis Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Sepsis Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Sepsis Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer